Skip to main content
. 2016 Sep 16;82(19):5763–5774. doi: 10.1128/AEM.01385-16

FIG 4.

FIG 4

EOP of ΦSA012 with anti-ORF103 and anti-ORF105 antibodies. Preimmune serum (pre-serum) was used in controls. The number of plaques observed in the presence of preimmune serum was set as 100%. Plaques were not detected (ND) in the presence of anti-ORF105 serum. Three biological replicates were conducted. Error bars indicate SD. *, P < 0.05; **, P < 0.01; ns, not significant.